Market Need Sepsis remains the leading hospital killer with a critical need for rapid, accurate diagnostics. Cytovale’s IntelliSep offers a under-10-minute biomechanical WBC analysis, enabling faster risk stratification and treatment decisions, which can be packaged as a hospital-wide early sepsis screening solution.

Hospital Commercialization With multiple C-suite appointments in 2024–2026 and a focused U.S. hospital deployment strategy, Cytovale is building a commercial engine across emergency departments. Target top-tier hospitals and large health systems seeking to reduce sepsis mortality and length of stay.

Expansion Opportunities Funding momentum and recent leadership additions signal scalability and go-to-market expansion. There are opportunities to cross-sell IntelliSep into inpatient wards, ICU settings, and telemedicine-linked care pathways that monitor infection surveillance.

Strategic Partnerships Partnership potential exists with health IT and diagnostics ecosystems leveraging existing tech stack (Azure, Salesforce, HubSpot, Docker) to integrate IntelliSep data with EHRs, dashboards, and hospital analytics for end-to-end sepsis care workflows.

Competitive Positioning Cytovale’s FDA-cleared rapid test differentiates from slower or less accurate sepsis assays. Emphasize cost- and time-to-diagnosis advantages to IDNs and hospital systems seeking to reduce sepsis-related mortality costs and capture savings highlighted by industry awards and notable funding.